Diabetes Asia Journal is an open-access journal, meaning that all content is freely available to the user or his/her institution without charge. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles in this journal without asking prior permission from the publisher or the author. This is the definition of open access, as defined by the Budapest Open Access Initiative (BOAI).
The articles in Diabetes Asia Journal under JHRC, Open Access, and are licensed under a Creative Commons Attribution 4.0 International License, visit http://creativecommons.org/licenses/by/4.0/, and the authors retain all rights, which permits unrestricted, non-commercial use, distribution, and reproduction in any medium, provided the work is properly cited.
https://portal.issn.org/resource/ISSN/3048-8192
Publisher
Diabetes Asia Journal under JHRC
Started
2024
Frequency
Quarterly
Language
English
Subject
Diabetes
Format
PDF
ISSN (Online)Journal DOI
3048-8192doi.org/10.62996/daj.10002024
1. Aims and Scope:
Diabetes Asia Journal under JHRC is an innovative, research, online, open-access, single-blind peer-reviewed Journal that accepts solicited and unsolicited manuscripts. Articles published in the Diabetes Asia Journal under JHRC are Superior-quality, clinical, and basic, influential research articles by established academic authors and new researchers. The paramount objective of the Journal is to encourage and promote distinguished research in diabetes, hypertension, maternal-fetal medicine, gestational diabetes, and NCD health, as well as inspire and motivate all contributors to advance the field. The articles published inDiabetes Asia Journal under JHRC include Editorial, Correspondence, Opinion Review, Frontier, Review, Minireview, Clinical Research, Basic Study, Meta-analysis, Evidence-based Medicine, Clinical Guidelines, Letter to the Editor, and Case Report.
Diabetes Asia Journal is published under JHRC and covers Diabetes Research, including NCDs, specifically in Central Asia, South Asia, Southeast Asia, and the Asia Pacific.2. APC:
Article processing charges are completely waived for 2 years from Jan 2024 to Jan 2026
All the articles are Open Access and are licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third-party material in this article are included in the article’s Creative Commons license unless stated otherwise in a credit line to the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
3. Diabetes Asia Journal
routinely screens article submissions for plagiarism through https://www.ithenticate.com/products/crossref-similarity-check and does not accept manuscripts where plagiarism is found.
4. A repository
A preprint can be deposited on the journal website, for which a DOI preprint will be given and made available until the article is published.
5. Diabetes Asia Journal under JHRC
is a publisher and a Member of Crossref with DOI: 10.62996
6. Focus and Scope
The Diabetes Asia Journal (Diabetes Asia J) [ISSN 3048-8192 (Online) under JHRC (Publisher) serves as the Quarterly Journal. This esteemed, multidisciplinary, peer-reviewed, open-access journal facilitates the exchange of scientific information across various disciplines, including medical, dental, pharmaceutical, nursing, and biological sciences. JHRC publishes the Journal and does not impose any article processing or submission fees. Diabetes Asia J has an internationally recognized editorial team comprising selected scientists and clinical experts across diverse basic and clinical medical science fields. We firmly adhere to the rigorous standards that the Committee on Publication Ethics (COPE) and the International Committee of Medical Journal Editors (ICMJE) outlined in all aspects of conducting, reporting, editing, and publishing scholarly research. Our mission at Diabetes Asia Journal is to swiftly disseminate ground-breaking experimental and clinical research findings that enhance healthcare outcomes.
We publish various content, including editorials, original articles, review articles, short communications, case reports, methods and techniques, and letters to the editor. We invite high-quality submissions reflecting laboratory and basic science research and clinical investigations. Contributions involving animal models and in vitro assays are also welcome. Upon online submission, articles will undergo a rigorous peer review. Accepted manuscripts are published immediately to ensure rapid international dissemination of knowledge. All submitted manuscripts must include a statement affirming that all human studies have been thoroughly reviewed by the appropriate ethics committee and conducted under the ethical standards outlined in the Declaration of Helsinki and its subsequent amendments.
Furthermore, it is mandatory to include a statement confirming that informed consent was obtained from all participants before their inclusion in the study. Reports on animal experiments must comply with the “Principles of Laboratory Animal Care”. The Editor-in-Chief reserves the unequivocal right to reject any manuscript that fails to meet these critical requirements. Each author listed must have made a significant contribution to the research. While our editorial team and referees are committed to ensuring the integrity of the published manuscripts, ultimate accountability for the accuracy and completeness of the reports lies solely with the authors. Authors are fully responsible for inaccuracies, misrepresentations, or failure to adhere to these stipulations.
7. Peer Review Process
The Diabetes Asia Journal (Diabetes Asia J) employs a rigorous double-blind peer review process designed to uphold the highest standards of research integrity. Each submission is evaluated by at least two expert reviewers who offer detailed critiques within two to four weeks. These reviewers meticulously assess the originality of the research, its impact on advancing the field, and the validity of the scientific methods employed. They identify any errors or shortcomings in the study’s design and methodology, critically evaluate the significance of the results, and ensure all references cited are accurate and complete. This comprehensive review process ensures that only the most impactful and scientifically sound research is published, contributing to advancing diabetes science and care.
8. Publication Frequency
The Diabetes Asia Journal (Diabetes Asia J) is a quarterly journal, committed to delivering cutting-edge research promptly. Each volume features a single comprehensive issue released once a year. What sets Diabetes Asia J apart is its dedication to rapid dissemination of knowledge—we publish individual articles as soon as they are ready, featuring them in our “ahead of print” section. This innovative approach allows researchers and practitioners to access vital findings promptly, before they are compiled into a complete issue. Join us in advancing scientific discovery and clinical practice with AJECR’s timely contributions to the field.
9. Open Access Policy
The Diabetes Asia J proudly adheres to the Creative Commons Attribution Non-Commercial No-Derivatives license. This allows readers to freely utilize and share our high-quality research for non-commercial purposes, provided proper credit is given to the original authors. Diabetes Asia J is dedicated to facilitating immediate access to its ground-breaking content, firmly believing that publicly available research fosters significant global knowledge exchange and accelerates scientific progress for all.
10. Archiving
The Diabetes Asia Journal is archived at http://archive.org, which ensures its permanent preservation and restoration.
The Diabetes Asia Journal (Diabetes Asia J) does not accept online advertising. All ads are subject to review and must comply with standard ethical policies. The journal reserves the right to remove ads whenever it deems necessary.
13. Plagiarism Policy
At Diabetes Asia J, we have zero tolerance for plagiarism in any submissions. All manuscripts submitted will undergo a rigorous plagiarism check before the review process commences, using Crossref Similarity Check powered by iThenticate. Any instance of plagiarism detected will result in the immediate rejection of the manuscript.
14. Peer Review Process
Upon submission, one of the Principal Editors will thoroughly evaluate all manuscripts. Manuscripts that fail to meet fundamental scientific principles or fall outside the scope of Diabetes Asia J will be rejected at this initial stage. Those who proceed will enter our peer review system, where they will be assigned to an Associate Editor and at least three expert reviewers specific to the relevant subject area. We enforce a single-blind peer review policy, ensuring that authors remain unaware of the reviewers’ identities. If necessary, the manuscript will be referred to a specialist/specialized statistical advisor for an in-depth evaluation. The Editors will make a decisive judgment based on the reviewers’ feedback, determining whether the manuscript is accepted outright (uncommon), requires minor or major revisions, or is outright rejected. Revised manuscripts will be resubmitted to the original reviewers, and possibly reviewed by an additional expert, before a final decision is rendered or further revisions are requested.
15. Peer Review Guidelines
Diabetes Asia J utilizes a single-anonymous review process and a single-blind peer review. In this system, the reviewers’ identities are not disclosed to the authors; however, reviewers will have access to the authors’ names.
16. Competing Interests
As a reviewer for Diabetes Asia J, you are responsible for maintaining the integrity of the peer review process. It is imperative that you carefully consider any potential competing interests, as these can introduce perceived or actual biases that may compromise the validity of a study. Competing interests can be financial or non-financial and may stem from professional or personal relationships with organizations or individuals. If you identify any competing interests, you must contact the editors immediately. The editors will determine whether to assign the review to you or find another reviewer. The editor must be informed of these competing interests to assess your feedback accurately.
17. Reviewer Assessment
The peer review process has three key objectives: to select papers suitable for publication in Diabetes Asia J, to enhance manuscript quality, and to provide constructive feedback. You are expected to evaluate the manuscript’s quality, validity, and relevance, and to provide clear justification for any significant concerns raised with the authors. Your focus should encompass originality, presentation, relevance to the journal’s readership, and the accuracy of methodology. Specifically, you will be asked to assess the manuscript based on the following: design and quality of data, adequate discussion and conclusions, methodology, and importance of the study related to new findings or valuable confirmations. Your attention to detail on the manuscript title is vital; it should be informative and concise. Similarly, the abstract must be clear, as many readers will only review the title and abstract. In your comments to the authors, you should begin with a concise summary of your observations about the paper. Do not suggest rejection or acceptance; these conclusions should be reserved for the confidential editor’s form. Following this summary, assess the abstract, introduction, methods and materials, results, and discussion. While minor comments on various manuscript sections are beneficial, if you believe the manuscript is unsuitable for publication, you need not provide extensive feedback to the authors. However, comments to the editor detailing your reasons for recommending revision or rejection are welcome and necessary.
18. Timeliness and Publication Process
Diabetes Asia J is committed to minimizing publication times, which are essential for the review process. If you cannot review a manuscript, you must inform us immediately. Generally, the review process takes 2-3 weeks, and one week for acceptance. Finally, the manuscript is published within one month of submission. If the manuscript is delayed, authors are informed. Adherence to deadlines is critical, and if you anticipate difficulty in meeting a timeline, notify the editorial office immediately, so they can inform the authors and adjust the system accordingly. Authors are informed if necessary to shorten the manuscript, reduce the number of tables and figures, and limit references as required. Be aware that editors may reject papers despite the reviewers’ recommendations, as the manuscript’s relevance to Medicine is paramount.
